147 related articles for article (PubMed ID: 16099884)
1. Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia.
Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; van Egmond HM; Willemze R; Falkenburg JH
Blood; 2005 Dec; 106(12):3955-7. PubMed ID: 16099884
[TBL] [Abstract][Full Text] [Related]
2. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
[TBL] [Abstract][Full Text] [Related]
3. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
[TBL] [Abstract][Full Text] [Related]
4. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
[TBL] [Abstract][Full Text] [Related]
6. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.
van Bergen CA; van Luxemburg-Heijs SA; de Wreede LC; Eefting M; von dem Borne PA; van Balen P; Heemskerk MH; Mulder A; Claas FH; Navarrete MA; Honders WM; Rutten CE; Veelken H; Jedema I; Halkes CJ; Griffioen M; Falkenburg JH
J Clin Invest; 2017 Feb; 127(2):517-529. PubMed ID: 28067665
[TBL] [Abstract][Full Text] [Related]
7. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation.
Torikai H; Akatsuka Y; Yatabe Y; Morishima Y; Kodera Y; Kuzushima K; Takahashi T
Int J Hematol; 2008 Jun; 87(5):467-473. PubMed ID: 18414982
[TBL] [Abstract][Full Text] [Related]
9. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
10. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
11. Minor histocompatibility antigens in human stem cell transplantation.
Falkenburg JH; van de Corput L; Marijt EW; Willemze R
Exp Hematol; 2003 Sep; 31(9):743-51. PubMed ID: 12962719
[TBL] [Abstract][Full Text] [Related]
12. [Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].
Tanaka J
Nihon Rinsho; 2003 Sep; 61(9):1512-9. PubMed ID: 14515717
[TBL] [Abstract][Full Text] [Related]
13. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
[TBL] [Abstract][Full Text] [Related]
14. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
Warren EH; Fujii N; Akatsuka Y; Chaney CN; Mito JK; Loeb KR; Gooley TA; Brown ML; Koo KK; Rosinski KV; Ogawa S; Matsubara A; Appelbaum FR; Riddell SR
Blood; 2010 May; 115(19):3869-78. PubMed ID: 20071660
[TBL] [Abstract][Full Text] [Related]
15. Type I-IFNs control GVHD and GVL responses after transplantation.
Robb RJ; Kreijveld E; Kuns RD; Wilson YA; Olver SD; Don AL; Raffelt NC; De Weerd NA; Lineburg KE; Varelias A; Markey KA; Koyama M; Clouston AD; Hertzog PJ; Macdonald KP; Hill GR
Blood; 2011 Sep; 118(12):3399-409. PubMed ID: 21719602
[TBL] [Abstract][Full Text] [Related]
16. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
Front Immunol; 2018; 9():3016. PubMed ID: 30619360
[TBL] [Abstract][Full Text] [Related]
17. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant.
Nishida T; Akatsuka Y; Morishima Y; Hamajima N; Tsujimura K; Kuzushima K; Kodera Y; Takahashi T
Br J Haematol; 2004 Mar; 124(5):629-35. PubMed ID: 14871250
[TBL] [Abstract][Full Text] [Related]
19. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
Dickinson AM; Wang XN; Sviland L; Vyth-Dreese FA; Jackson GH; Schumacher TN; Haanen JB; Mutis T; Goulmy E
Nat Med; 2002 Apr; 8(4):410-4. PubMed ID: 11927949
[TBL] [Abstract][Full Text] [Related]
20. Minor histocompatibility antigens: past, present, and future.
Spierings E
Tissue Antigens; 2014 Oct; 84(4):374-60. PubMed ID: 25262921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
